MIK665
Based on 18 publication(s) in Google Scholar
MIK665 (S-64315), derived from S63845, is a myeloid cell leukemia sequence 1 (MCL1) inhibitor. MIK665 has an IC50 of 1.81 nM for MCL1.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.11%
- CAS No.: 1799631-75-6
- Formule: C47H44ClFN6O6S
- Masse moléculaire:875.41
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) MIK665
More- Cell Stem Cell. 2026 Jun 4;33(6):982-999.e8. [Abstract]
- Nat Commun. 2025 Aug 21;16(1):7689. [Abstract]
- Nat Commun. 2025 Aug 21;16(1):7688. [Abstract]
- Mol Cell. 2024 Apr 4;84(7):1338-1353.e8. [Abstract]
- Cell Death Dis. 2025 Mar 12;16(1):170. [Abstract]
- Cell Death Dis. 2024 Mar 8;15(3):198. [Abstract]
- Cell Death Dis. 2020 Jun 8;11(6):443. [Abstract]
- Cancer Lett. 2023 Feb 1:554:216028. [Abstract]
- J Invest Dermatol. 2022 Jul;142(7):1912-1922.e7. [Abstract]
- Pharmaceuticals (Basel). 2021 Jul 30;14(8):749. [Abstract]
- Cancers (Basel). 2020 Aug 5;12(8):2182. [Abstract]
- EJC Paediatr Oncol. 2024 Jun 3.
- Melanoma Res. 2023 Oct 1;33(5):345-356. [Abstract]
- bioRxiv. 2025 Oct 10.
- Leiden University. 2025.
- Patent. US20230116602A1.
- Patent. US20220347180A1.
- University of Colorado. 2020 Dec.
Customer Validation & Images
-
Flow Cytometry
-
In Vivo Efficacy Study
-
WB
-
Cell Imaging/Staining
-
Bio/Physico-chemical Assay
Activité biologique
|
Mcl-1 1.81 nM (IC50) |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| NCI-H929 | IC50 |
1.7 nM
Compound: 9m; S64315; MIK665
|
Antiproliferative activity against human NCI-H929 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Antiproliferative activity against human NCI-H929 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 33146521] |
MIK665 (S-64315) has similar synergistic effects as S63845, when combined with ABT-199. The combination S64315 (0.156-10 μM) and ABT-199 (625 nM) has similar efficacy in reducing the cell viability of representative melanoma lines (MB2141, MB3616, MB3961, MB4667, A375, and 1205Lu cells)[1].
MIK665 is extracted from patent WO2016207225A1, compound Preparation 13, and inhibits H929 cell with an IC50 of 250 nM[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1799631-75-6
-
Appearance Solid
-
Masse moléculaire 875.41
-
Formule C47H44ClFN6O6S
-
Color White to off-white
-
SMILES
OC([C@@H](CC(C=CC=C1)=C1OCC2=CC=NC(C3=CC=CC=C3OC)=N2)OC4=C5[C@]([C@]6=C(C)C(Cl)=C(OCCN7CCN(C)CC7)C=C6)=C(C8=CC=C(F)C=C8)SC5=NC=N4)=O
-
Synonyms
S-64315
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (18)
-
Journal Impact Factor
-
Most Recent
-
Cell Stem Cell
Leukemic stem cell subtypes determine venetoclax resistance and therapeutic vulnerabilities in AML. [Abstract]2026 Jun 4;33(6):982-999.e8. PMID: 42102807 -
Nat Commun
Small round cell sarcoma tumoroid biobank reveals CIC::DUX4 sarcoma vulnerability to MCL-1 inhibition. [Abstract]2025 Aug 21;16(1):7689. PMID: 40841360 -
Nat Commun
Patient-derived tumoroids from CIC::DUX4 rearranged sarcoma identify MCL1 as a therapeutic target. [Abstract]2025 Aug 21;16(1):7688. PMID: 40841513
MIK665 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Aug 21;16(1):7688. [Abstract]
MIK665 (S-64315) (10-50 nM; 24 h) effectively and rapidly induced cell death of CDS-ZH003.
MIK665 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Aug 21;16(1):7688. [Abstract]
MIK665 (S-64315) (20 mg/kg; i.v.; twice a week for 3 weeks) regressed tumors and significantly prolonged the survival of NSG mice.
-
Mol Cell
Anti-apoptotic MCL-1 promotes long-chain fatty acid oxidation through interaction with ACSL1. [Abstract]2024 Apr 4;84(7):1338-1353.e8. PMID: 38503284
MIK665 purchased from MedChemExpress. Usage Cited in: Mol Cell. 2024 Apr 4;84(7):1338-1353.e8. [Abstract]
MIK665 (S-64315) (500 nM) stabilized MCL-1 of 293T cellsbut repressed the ability of human MCL-1 to co-precipitate with ACSL1 and BIM.
MIK665 purchased from MedChemExpress. Usage Cited in: Mol Cell. 2024 Apr 4;84(7):1338-1353.e8. [Abstract]
MIK665 (S-64315) (500 nM) significantly repressed the utilization of oleate-containing lipid droplets in hMCL-1 MEFs.
MIK665 purchased from MedChemExpress. Usage Cited in: Mol Cell. 2024 Apr 4;84(7):1338-1353.e8. [Abstract]
MCL-1 inhibitor MIK665 (S-64315) (50 mg/kg; i.v.; once daily for 5 d) significantly repressed palmitate oxidation in heart mitochondria from C57BL/6J mice.
-
Cell Death Dis
Both direct and indirect suppression of MCL1 synergizes with BCLXL inhibition in preclinical models of gastric cancer. [Abstract]2025 Mar 12;16(1):170. PMID: 40075071 -
Cell Death Dis
MCL1 inhibition targets Myeloid Derived Suppressors Cells, promotes antitumor immunity and enhances the efficacy of immune checkpoint blockade. [Abstract]2024 Mar 8;15(3):198. PMID: 38459020 -
Cell Death Dis
MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells. [Abstract]2020 Jun 8;11(6):443. PMID: 32513939
MIK665 purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2020 Jun 8;11(6):443. [Abstract]
S64315+A-1331852 and S64315+ABT-263 significantly reduces cell viability compared with DMSO or with single drug treated conditions in all melanoma cell lines at sub-micromolar doses.
-
Cancer Lett
High-content drug screening in zebrafish xenografts reveals high efficacy of dual MCL-1/BCL-XL inhibition against Ewing sarcoma. [Abstract]2023 Feb 1:554:216028. PMID: 36462556 -
J Invest Dermatol
Expression Differences in BCL2 Family Members between Uveal and Cutaneous Melanomas Account for Varying Sensitivity to BH3 Mimetics. [Abstract]2022 Jul;142(7):1912-1922.e7. PMID: 34942200 -
Pharmaceuticals (Basel)
2021 Jul 30;14(8):749. PMID: 34451846 -
Cancers (Basel)
Simultaneously Inhibiting BCL2 and MCL1 Is a Therapeutic Option for Patients with Advanced Melanoma. [Abstract]2020 Aug 5;12(8):2182. PMID: 32764384 -
-
Melanoma Res
2023 Oct 1;33(5):345-356. PMID: 37467061 -
-
-
-
-
Solvant et solubilité
DMSO : ≥ 125 mg/mL (142.79 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (2.38 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (277 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.1423 mL | 5.7116 mL | 11.4232 mL | 28.5580 mL |
| 5 mM | 0.2285 mL | 1.1423 mL | 2.2846 mL | 5.7116 mL | |
| 10 mM | 0.1142 mL | 0.5712 mL | 1.1423 mL | 2.8558 mL | |
| 15 mM | 0.0762 mL | 0.3808 mL | 0.7615 mL | 1.9039 mL | |
| 20 mM | 0.0571 mL | 0.2856 mL | 0.5712 mL | 1.4279 mL | |
| 25 mM | 0.0457 mL | 0.2285 mL | 0.4569 mL | 1.1423 mL | |
| 30 mM | 0.0381 mL | 0.1904 mL | 0.3808 mL | 0.9519 mL | |
| 40 mM | 0.0286 mL | 0.1428 mL | 0.2856 mL | 0.7140 mL | |
| 50 mM | 0.0228 mL | 0.1142 mL | 0.2285 mL | 0.5712 mL | |
| 60 mM | 0.0190 mL | 0.0952 mL | 0.1904 mL | 0.4760 mL | |
| 80 mM | 0.0143 mL | 0.0714 mL | 0.1428 mL | 0.3570 mL | |
| 100 mM | 0.0114 mL | 0.0571 mL | 0.1142 mL | 0.2856 mL |
MIK665 Related Classifications
HY-112218 Related Classifications
Powered by Bioz